CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 65 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2017. The put-call ratio across all filers is 0.58 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $12,447,000 | +113.0% | 1,719,247 | +2.7% | 0.23% | +112.0% |
| Q2 2020 | $5,844,000 | +43.6% | 1,674,447 | -39.1% | 0.11% | -5.3% |
| Q1 2020 | $4,071,000 | -26.2% | 2,750,616 | -2.2% | 0.11% | -13.6% |
| Q4 2019 | $5,515,000 | -65.4% | 2,813,565 | -9.7% | 0.13% | -75.3% |
| Q3 2019 | $15,953,000 | -29.0% | 3,115,865 | -0.7% | 0.53% | -16.0% |
| Q2 2019 | $22,471,000 | -42.5% | 3,138,365 | +6.6% | 0.64% | -44.4% |
| Q1 2019 | $39,093,000 | +68.4% | 2,943,765 | -0.2% | 1.14% | +22.6% |
| Q4 2018 | $23,208,000 | -30.0% | 2,948,865 | -1.5% | 0.93% | -8.5% |
| Q3 2018 | $33,169,000 | -16.4% | 2,993,565 | +1.2% | 1.02% | -24.3% |
| Q2 2018 | $39,693,000 | +3.4% | 2,957,765 | +0.1% | 1.35% | -9.1% |
| Q1 2018 | $38,393,000 | +108.4% | 2,955,565 | +47.6% | 1.48% | +85.1% |
| Q4 2017 | $18,421,000 | +38.8% | 2,002,265 | +21.6% | 0.80% | +22.3% |
| Q3 2017 | $13,276,000 | – | 1,647,100 | – | 0.66% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |